The FDA has removed the risk evaluation and mitigation strategies (REMS) program requirement for Tryvio (aprocitentan).

MMS, an award-winning, data-focused clinical research organization (CRO), is showcasing its expansion as a tech-enabled, full-service Risk Evaluation and Mitigation Strategies (REMS) solutions ...

Unless you’re lucky to fly in a class with a lie-flat seat, you’re unlikely to step off a long-haul flight having had a ...

Medical experts reveal the surprising conditions that can lead to death during sleep, from cardiac arrhythmias to sleep apnea ...

The FDA approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in adults with complement 3 glomerulopathy ...

Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...

The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in ...

The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

US FDA approves Novartis’ oral Fabhalta for treatment of adults with C3 glomerulopathy: Basel Saturday, March 22, 2025, 09:00 Hrs [IST] Novartis announced that oral Fabhalta (ip ...

Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, ...

Highlights,Institutional investors have significantly expanded their positions in Simulations Plus.,The company specializes ...